Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

Synaptogenix (NASDAQ:TAOX) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Synaptogenix has a consensus rating of “Sell”.

Synaptogenix Stock Performance

Shares of TAOX stock opened at $5.70 on Friday. The company has a market cap of $42.58 million, a PE ratio of -0.28 and a beta of 1.68. The company’s fifty day simple moving average is $4.71 and its 200-day simple moving average is $5.82. Synaptogenix has a 52 week low of $1.84 and a 52 week high of $11.98.

Synaptogenix (NASDAQ:TAOX) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. The business had revenue of ($2.46) million for the quarter.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.